We are live on ! Find out more
FRTX

Fresh Tracks Therapeutics, Inc. Common Stock

Delisted

FRTX was delisted on the 18th of December, 2023.

28 hedge funds and large institutions have $11.5M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% more call options, than puts

Call options by funds: $127K | Put options by funds: $65K

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

18% less capital invested

Capital invested by funds: $14.1M → $11.5M (-$2.57M)

26% less funds holding

Funds holding: 3828 (-10)

91% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 11

Holders
28
Holders Change
-10
Holders Change %
-26.32%
% of All Funds
0.64%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
8
Reduced
9
Closed
11
Calls
$127K
Puts
$65K
Net Calls
+$62K
Net Calls Change
+$47K

FRTX Hedge Fund Activity: Q2 2018 in Review

28 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q2 2018, worth a combined $11.5M — down 18% from $14.1M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of FRTX and 1 opened new positions — a net loss of 10 holders — while 9 trimmed existing stakes and 8 added.

The largest buyer was Armistice Capital, adding an estimated $3.08M. The largest seller was Eventide Asset Management, cutting an estimated $2.09M.

  • 28 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q2 2018, down from 38 in Q1 2018.
  • Funds reported $11.5M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q2 2018, down 18% quarter-over-quarter.
  • 1 fund opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q2 2018 and 11 closed out, a net change of -10 holders.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q2 2018 was Armistice Capital, an estimated $3.08M added.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q2 2018 was Eventide Asset Management, an estimated $2.09M sold.

Based on aggregated 13F filings for Q2 2018.